Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Department of Immunology, Genetics, and Pathology, Biomedical Center, SciLifeLab Uppsala, Uppsala University, Uppsala, Sweden.
Int J Cancer. 2021 Jun 15;148(12):3051-3059. doi: 10.1002/ijc.33482. Epub 2021 Feb 17.
Primary screening with human papillomavirus (HPV) test is more effective in reducing cervical cancer incidence than cytology and it also offers the opportunity to self-sample. We conducted a randomized study to compare vaginal self-sampling with cervical sampling by medical professionals for HPV testing concerning prevalence of HPV and detection of cervical intraepithelial neoplasia (CIN) of grade 2 or worse (CIN2+) or grade 3 or worse (CIN3+) in primary screening. In total, 11 951 women aged 30-60 years were randomized into two groups, 5961 for self-sampling (SS arm) and 5990 for sampling by medical professionals (SMP arm). Sampling was performed with a RoversViba-brush in the SS arm and a cytobrush in the SMP arm. All samples were applied to an indicating FTA elute card and analyzed for HPV using a clinically validated real-time PCR test (hpVIR). All HPV-positive women performed repeated sampling about 6 months later using the same procedure as used initially. All HPV-positive women in the second sampling were referred to colposcopy. The prevalence of HPV in the first test did not differ between the SS arm (6.8%, 167/2466) and the SMP arm (7.8%, 118/1519) (P = .255). The prevalence of CIN2+ per 1000 screened women was 17 (43/2466 × 1000) (95%CI 13-24) in the SS arm and 21 (32/1519 × 1000) (95%CI 15-30) in the SMP arm. For CIN3+, the prevalence per 1000 screened women was 14 (35/2466 × 1000) (95%CI 10-20) in the SS arm and 15 (23/1519 × 1000) (95%CI 10-23) in the SMP arm. In conclusion, self-sampling and sampling by medical professionals showed the same prevalence of HPV and detection rate of CIN2+ and CIN3+ in histology.
在降低宫颈癌发病率方面,人乳头瘤病毒(HPV)检测的初步筛查比细胞学检查更有效,并且还提供了自我采样的机会。我们进行了一项随机研究,比较了阴道自我采样与医疗专业人员进行 HPV 检测的宫颈采样,以比较 HPV 的流行率以及检测宫颈上皮内瘤变(CIN)2 级或更高级别(CIN2+)或 3 级或更高级别(CIN3+)的发生率。共有 11951 名 30-60 岁的女性被随机分为两组,5961 名进行自我采样(SS 组),5990 名进行医疗专业人员采样(SMP 组)。SS 组使用 RoversViba 刷进行采样,SMP 组使用细胞刷进行采样。所有样本均应用于指示性 FTA 洗脱卡,并使用经过临床验证的实时 PCR 检测(hpVIR)分析 HPV。所有 HPV 阳性女性均在大约 6 个月后再次使用最初使用的相同程序进行重复采样。第二次采样中的所有 HPV 阳性女性均转介行阴道镜检查。首次检测中,SS 组(6.8%,167/2466)和 SMP 组(7.8%,118/1519)的 HPV 流行率无差异(P=0.255)。每 1000 名筛查女性的 CIN2+患病率在 SS 组为 17(43/2466×1000)(95%CI 13-24),在 SMP 组为 21(32/1519×1000)(95%CI 15-30)。对于 CIN3+,每 1000 名筛查女性的患病率在 SS 组为 14(35/2466×1000)(95%CI 10-20),在 SMP 组为 15(23/1519×1000)(95%CI 10-23)。总之,自我采样和医疗专业人员采样在 HPV 流行率以及 CIN2+和 CIN3+的组织学检出率方面显示出相同的结果。